MedMira to Submit Cutting-Edge Rapid HIV Test for WHO Prequalification

Complete testing solution optimizes time and money spent on programs to save more lives

HALIFAX, March 18, 2014 /CNW/ - MedMira Inc. (TSXV: MIR) will submit a new application for its most advanced Reveal Rapid HIV Antibody Test (Reveal HIV) to the WHO Prequalification of Diagnostics Programme.  The latest version of Reveal HIV, recently approved in the European Union, delivers faster and more convenient point-of-care testing in the field through its simplified test procedure and the direct use of whole blood specimens.   These new features are also in the Reveal and Multiplo products currently being commercialized in preparation for FDA submission.

The MedMira management team made the decision to submit its most advanced Reveal HIV test to the WHO for prequalification based on the company's commitment to offer state-of-the-art technology and testing solutions to every corner of the world. Prequalification of the latest Reveal HIV format will also enable MedMira's global strategic partners to bring the best technology and products to all markets where care providers and patients can benefit from faster, more cost-effective testing solutions. As MedMira rolls out this advanced version of Reveal HIV around the globe, legacy products will be phased out and the company will no longer support previous versions of the test, including the format originally submitted to the WHO for prequalification.

"Healthcare providers around the world are demanding the most advanced technology that qualified rapid test developers have to offer in order to meet the increasing need for screening tools that help prevent and control the spread of deadly diseases like HIV.  By submitting Reveal HIV, built on the latest advances in our Rapid Vertical Flow Technology, for prequalification, MedMira is answering the WHO's call for state-of-the art, innovative products needed in their programs," said Hermes Chan, CEO, MedMira Inc.

Chan added, "Cost efficiency combined with high quality tests are critical to all government and non-government organizations running testing programs.  MedMira is creating new modelling tools to help care providers optimize their program outputs and maximize available budgets, especially important in regions where large scale screening programs have the most impact.  Our goal is to provide a comprehensive testing solution that includes the most advanced diagnostic technology, the highest quality tests, and optimization tools to save lives."

About MedMira

MedMira is a leading developer and manufacturer of vertical flow rapid diagnostics. The Company's tests provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as HIV and hepatitis C in just three easy steps. The Company's tests are sold under the Reveal®, Multiplo™ and Miriad™ brands in global markets. Based on its patented Rapid Vertical Flow Technology™, MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit medmira.com.

This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events including statements regarding possible approval and launch of new products, future growth, and new business opportunities.  Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: MedMira Inc.

MedMira Contact:
Andrea Young, Corporate Communications
T. 902-450-1588
E. [email protected]